The clinical use of blood-test factors for Alzheimer's disease: improving the prediction of cerebral amyloid deposition by the QPLEXTM Alz plus assay kit.

Experimental & Molecular Medicine
Haeng Jun KimInhee Mook-Jung

Abstract

Alzheimer's disease (AD) is the leading cause of dementia, and many studies have focused on finding effective blood biomarkers for the accurate diagnosis of this disease. Predicting cerebral amyloid deposition is considered the key for AD diagnosis because a cerebral amyloid deposition is the hallmark of AD pathogenesis. Previously, blood biomarkers were discovered to predict cerebral amyloid deposition, and further efforts have been made to increase their sensitivity and specificity. In this study, we analyzed blood-test factors (BTFs) that can be commonly measured in medical health check-ups from 149 participants with cognitively normal, 87 patients with mild cognitive impairment, and 64 patients with clinically diagnosed AD dementia with brain amyloid imaging data available. We demonstrated that four factors among regular health check-up blood tests, cortisol, triglyceride/high-density lipoprotein cholesterol ratio, alanine aminotransferase, and free triiodothyronine, showed either a significant difference by or correlation with cerebral amyloid deposition. Furthermore, we made a prediction model for Pittsburgh compound B-positron emission tomography positivity, using BTFs and the previously discovered blood biomarkers, the ...Continue Reading

References

Nov 13, 2002·Neurology·N D PrinsUNKNOWN Rotterdam Scan Study
May 19, 2004·Archives of Neurology·Christiane ReitzRichard Mayeux
Jul 26, 2005·Neuroscience Letters·Antimo D'AnielloPatrizia Spinelli
Mar 17, 2006·Nature·Sylvain LesnéKaren H Ashe
Jan 24, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Graeme J O'KeefeChristopher C Rowe
Apr 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Eric M ReimanRichard J Caselli
Nov 13, 2009·Annals of the New York Academy of Sciences·Owen M WolkowitzVictor I Reus
Nov 26, 2011·Biochimica Et Biophysica Acta·Anton ForsbergAgneta Nordberg
Nov 21, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Rik OssenkoppeleBart N M van Berckel
Nov 21, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Susan M LandauUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Dec 13, 2012·Radiology·Jennifer L ShafferUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Jan 9, 2013·Nature Reviews. Neurology·Chia-Chen LiuGuojun Bu
Mar 13, 2013·Lancet Neurology·Victor L VillemagneUNKNOWN Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group
Jan 25, 2016·Trends in Cognitive Sciences·Susanne VogelLars Schwabe
Dec 18, 2016·Neurology·Gilda E EnnisScott D Moffat
Mar 24, 2017·Alzheimer's Research & Therapy·Jong-Chan ParkInhee Mook-Jung
Jul 18, 2017·Acta Pharmacologica Sinica·Guo-Fang ChenH Eric Xu
Jul 26, 2017·Scientific Reports·Agostino ChiaravallotiOrazio Schillaci
Aug 19, 2017·Alzheimer's Research & Therapy·Hyo Jung ChoiUNKNOWN KBASE Research Group
Feb 9, 2018·Nature·Akinori NakamuraKatsuhiko Yanagisawa
Mar 9, 2019·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Yi SuTammie L S Benzinger
Mar 19, 2019·Frontiers in Aging Neuroscience·Sami Ouanes, Julius Popp
Aug 1, 2019·JAMA Network Open·Kwangsik NhoUNKNOWN Alzheimer’s Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium
Oct 13, 2019·Progress in Neurobiology·Jong-Chan ParkInhee Mook-Jung
Jan 8, 2021·Alzheimer's Research & Therapy·Jong-Chan ParkInhee Mook-Jung

❮ Previous
Next ❯

Software Mentioned

MedCalc
KBASE
GraphPad Prism

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.